MRP Under Process
Official PMBI MRP is being updated for catalog code 2519.
Locate Jan Aushadhi KendraClinical Overview
Combi Kit of Torasemide (20mg) Tablets and Eplerenone (25mg) Tablets combines a long-acting loop diuretic with a selective mineralocorticoid receptor antagonist (MRA). Torasemide delivers potent, predictable loop diuresis with minimal urinary potassium wasting compared to furosemide. Eplerenone selectively blocks aldosterone without binding to androgen or progesterone receptors, completely eliminating gynecomastia and sexual side effects while preventing hypokalemia. Indicated for severe edema, chronic heart failure with reduced ejection fraction (HFrEF), and refractory hypertension.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning with food and water. Follow kit compartment instructions. Periodic electrolyte monitoring is mandatory.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Increased urination, dizziness, fatigue, diarrhea. Rare/Severe: Severe hyperkalemia, dehydration, hypotension, and renal dysfunction.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in serum potassium > 5.0 mEq/L, severe renal impairment (eGFR < 30 mL/min), and co-administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin). Does NOT cause gynecomastia.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.
Torsemide Tablets 20 mg
Torsemide Tablets 20 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.
Eplerenone Tablets 25 mg
Eplerenone Tablets 25 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.
Torsemide 10mg + Spironolactone 50mg Tablets
Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.
Torsemide Tablets 40mg
Torsemide / Torasemide Tablets (5mg, 40mg) is a long-acting pyridine-sulfonylurea loop diuretic on the WHO Model List framework. It inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of Henle's loop, blocking active sodium and chloride reabsorption. It features high oral bioavailability (~80%), consistent absorption regardless of intestinal mucosal edema, and an extended duration of action (~12 hours) with anti-aldosteronergic properties that cause less potassium wasting than furosemide. Indicated for treatment of edema associated with congestive heart failure, chronic kidney disease (CKD), nephrotic syndrome, hepatic cirrhosis, and management of hypertension.